AZD1480 Can Inhibit the Biological Behavior of Ovarian Cancer SKOV3 Cells in vitro |
Sun, Zhao-Ling
(Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital)
Tang, Ya-Juan (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) Wu, Wei-Guang (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) Xing, Jun (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) He, Yan-Fang (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) Xin, De-Mei (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) Yu, Yan-Li (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) Yang, Yang (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) Han, Ping (Department of Gynecology and Obstetrics, HeBei United University Affiliated Hospital) |
1 | Alberts DS, Hannigan EV, Liu PY, et a1 (2006). Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol Oncol, 100, 133-8. DOI ScienceOn |
2 | Bid HK, Oswald D, Li C, et al (2012). Anti-Angiogenic Activity of a Small Molecule STAT3 Inhibitor LLL12. PLoS One, 7, e35513. DOI |
3 | Bromberg JF, Wrzeszczynska MH, Devgan G, et al (1999). STAT3 as an oncogene. Cell, 98, 295-303. DOI ScienceOn |
4 | Couto JP, Almeida A, Daly L, et al (2012). AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines. PLoS One, 7, e46869. DOI |
5 | de Groot J, Liang J, Kong LY, et al (2012). Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma. Oncotarget, 3, 1036-48. |
6 | Guo W, Wu S, Wang L, et al (2011). Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS One, 6, e28487. DOI ScienceOn |
7 | Hedvat M, Huszar D, Herrmann A, et al (2009). The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell, 16, 487-97. DOI ScienceOn |
8 | Jing N, Li Y, Xiong W, et al (2004). G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res, 64, 6603-9. DOI ScienceOn |
9 | Kandala PK, Srivastava SK (2012). Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov Ther, 6, 94-101. |
10 | Lai SY, Johnson FM (2010). Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Clini Drug Resist Updat, 13, 67-78. DOI ScienceOn |
11 | Leong P L, Andrews G A, Johnson D E, et a1(2003). Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA, 100, 4138-43. DOI ScienceOn |
12 | Loveless ME, Lawson D, Collins M, et al (2012). Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.Neoplasia, 14, 54-64. |
13 | McFarland BC, Ma JY, Langford CP, et al (2011). Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther, 10, 2384-93. DOI |
14 | Monk BJ, Tewari KS, Koh WJ(2007). Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol, 25, 2952-65. DOI ScienceOn |
15 | Piccart MJ, Bertelsen K, Stuart G, et a1 (2003). Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer, 13,144-8. DOI ScienceOn |
16 | Ptak A, Gregoraszczuk EL (2012). Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates theJAK/Stat, MAPK/ERK and PI3K/Akt signalling pathways in human ovarian cancer cell. Toxicol Lett, 210, 332-7. DOI ScienceOn |
17 | Scuto A, Krejci P, Popplewell L, et al (2011). The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia, 25, 538-50 DOI ScienceOn |
18 | Shin DS, Kim HN, Shin KD, et al (2009). Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res, 69, 193-202. DOI ScienceOn |
19 | Shirali S, Aghaei M, Shabani M, et al (2013). Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in humanovarian cancer cell line OVCAR-3. Tumour Biol, 34, 1085-95. DOI ScienceOn |
20 | Shodeinde AL, Barton BE (2012). Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco Targets Ther, 5, 119-25. |
21 | Skirnisdottir I, Seidal T (2013). Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer. Cancer Genomics Proteomics, 10, 27-34. |
22 |
Son DS, Kabir SM, Dong YL, et al (2012). Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of I |
23 | Subramaniam A, Shanmugam MK, Perumal E, et al (2013). Potential role of signal transducer and activator of transcription (STAT) 3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta, 1835, 46-60. |
24 | Swiatek-Machado K, Kaminska B (2013). STAT signaling in glioma cells. Adv Exp Med Biol, 986, 189-208. DOI |
25 | Thigpen JT, Vance RB, Khansur T (1993). Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer, 71, 1559-64. DOI ScienceOn |
26 | Wang X, Crowe PJ, Goldstein D, et al (2012). STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review). Int J Oncol, 41, 1181-91. |
27 | Yang CL, Liu YY, Ma YG, et al (2012). Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One,7, e37960. DOI |
![]() |